PhRMA responds to NORD
Pharmaceutical Research & Manufacturers of America maintains that its ads on the importance of patent protections for drugs to treat orphan diseases are "accurate and fair" in June 11 letter to the National Organization for Rare Diseases. "Many diseases are rare but not eligible for orphan drug status," PhRMA's response to NORD's June 6 letter states (1"The Pink Sheet" June 10, In Brief)...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."